| Patents for A61K 48 - Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy (86,964) |
|---|
| 05/09/1997 | WO1997016221A2 Genetic induction of receptors for targeted radiotherapy |
| 05/09/1997 | WO1997016209A1 Expression of cyclin g1 in tumors |
| 05/09/1997 | WO1997016206A1 Bladder nuclear matrix proteins and their use in detecting and treating cell proliferative disorders |
| 05/09/1997 | WO1997016170A1 Treatment of a coronary condition by delivery of therapeutics to the pericardial space |
| 05/09/1997 | WO1997016169A1 Treatment of a cardiovascular indication by delivery of therapeutics to the pericardial space |
| 05/09/1997 | WO1997016064A1 Methods and compositions for the reduction of xenotransplantation rejection |
| 05/09/1997 | CA2236419A1 Neurogenic differentiation (neurod) genes and proteins |
| 05/09/1997 | CA2234102A1 Genetic induction of receptors for targeted radiotherapy |
| 05/09/1997 | CA2233250A1 Use of protein gax for treating cancer |
| 05/09/1997 | CA2209314A1 Bladder nuclear matrix proteins and their use in detecting and treating cell proliferative disorders |
| 05/07/1997 | EP0771362A1 Genetic diagnosis of prostate cancer |
| 05/07/1997 | EP0771355A1 A method for large scale plasmid purification |
| 05/07/1997 | EP0771350A1 Growth control for cells encapsulated within bioartificial organs |
| 05/07/1997 | EP0771215A1 Retroviral transduction of cells using soluble complement inhibitors |
| 05/07/1997 | EP0771147A1 Compositions and methods for enhanced tumor cell immunity in vivo |
| 05/07/1997 | EP0771146A1 Fibrin(ogen) degradation and clot lysis by fibrinolytic matrix metalloproteinase |
| 05/07/1997 | EP0656747A4 Composition and method for altering dna sequences by homologous recombination. |
| 05/07/1997 | EP0566571B1 Diagnosis of metastatic cancer by the mts-1 gene |
| 05/07/1997 | DE19540902A1 Protein mit Anti-Tumorwirkung Protein with anti-tumor activity |
| 05/07/1997 | CN1149319A Angiostatin and method of use for inhibition of Angiogenesis |
| 05/07/1997 | CN1149317A DNA sequences |
| 05/06/1997 | US5627274 Antisense oligonucleotides which combat aberrant splicing and methods of using the same |
| 05/06/1997 | US5627264 Chimeric complement inhibitor proteins |
| 05/06/1997 | US5627158 Antisense oligonucleotides of human regulatory subunit RI-.sub.α of camp dependent protein kinases for the treatment of cancer |
| 05/06/1997 | US5627059 Cells and non-human organisms containing predetermined genomic modifications and positive-negative selection methods and vectors for making same |
| 05/06/1997 | US5627055 Finderons and methods of their preparation and use |
| 05/06/1997 | US5627053 2'deoxy-2'-alkylnucleotide containing nucleic acid |
| 05/06/1997 | US5627043 Production of proteins with dibasic amino acids and cleavage |
| 05/02/1997 | EP0770680A2 Lymphocyte-associated cell surface protein |
| 05/02/1997 | EP0770624A2 Peptide capable of inducing immune response to human gastric cancer and agent containing it for preventing or treating human gastric cancer |
| 05/02/1997 | EP0770140A1 Nucleic acid containing composition, preparation and uses of same |
| 05/02/1997 | EP0770137A1 Improvements in production of proteins in host cells |
| 05/02/1997 | EP0770133A1 Adenovirus comprising a gene coding for an no synthase |
| 05/02/1997 | EP0770129A1 Zinc finger protein derivatives and methods therefor |
| 05/02/1997 | EP0770087A1 Human elastase iv |
| 05/02/1997 | EP0770086A1 Macrophage migration inhibitory factor-3 |
| 05/02/1997 | EP0769968A1 Retroviral vectors produced by producer cell lines resistant to lysis by human serum |
| 05/02/1997 | EP0769942A1 Use of a cationic amphipathic compound as a transfection agent, vaccine additive or drug |
| 05/02/1997 | EP0769903A1 Inducible nitric oxide synthase gene for treatment of disease |
| 05/02/1997 | EP0769902A1 Methods for reducing hyperacute rejection of xenografts |
| 05/01/1997 | WO1997015686A1 Diagnosis of susceptibility to cancer and treatment thereof |
| 05/01/1997 | WO1997015680A1 Cationic polyacrylates and poly(alkyl) acrylates or the corresponding acrylamides for use in synthetic transfection or blocking systems |
| 05/01/1997 | WO1997015668A2 Methods and compositions comprising glut-2 and glut-2 chimeras |
| 05/01/1997 | WO1997015666A1 Therapeutic antiangiogenic compositions and methods |
| 05/01/1997 | WO1997015663A1 A novel haemopoietin receptor and genetic sequences encoding same |
| 05/01/1997 | WO1997015662A2 Method and reagent for the treatment of diseases or conditions related to levels of vascular endothelial growth factor receptor |
| 05/01/1997 | WO1997015655A2 New artificial tissue, method for the production and the use thereof |
| 05/01/1997 | WO1997015330A1 Hyaluronic acid as dna carrier for gene therapy and vegf antisense dna to treat abnormal retinal vascularization |
| 05/01/1997 | WO1997015310A1 In vitro growth of functional islets of langerhans and in vivo uses thereof |
| 05/01/1997 | WO1997015195A1 Hybrid matrix implants and explants |
| 05/01/1997 | CA2235685A1 Hyaluronic acid as dna carrier for gene therapy and vegf antisense dna to treat abnormal retinal vascularization |
| 05/01/1997 | CA2235509A1 In vitro growth of functional islets of langerhans and in vivo uses thereof |
| 05/01/1997 | CA2235368A1 Method and reagent for the treatment of diseases or conditions related to levels of vascular endothelial growth factor receptor |
| 05/01/1997 | CA2232241A1 Diagnosis of susceptibility to cancer and treatment thereof |
| 04/29/1997 | US5625047 Enzymatic RNA molecules |
| 04/29/1997 | US5624837 Nucleic acid encoding chimeric complement inhibitor proteins |
| 04/29/1997 | US5624830 Selectivity killing mammalian host cells in vitro |
| 04/29/1997 | US5624823 DNA encoding procine interleukin-10 |
| 04/29/1997 | US5624820 Episomal expression vector for human gene therapy |
| 04/24/1997 | WO1997014808A2 Herpesvirus vectors and their uses |
| 04/24/1997 | WO1997014806A2 Delivery of biologically active polypeptides |
| 04/24/1997 | WO1997014802A1 Novel adherence factors of non pathogenic microorganisms and applications thereof for screening microorganisms for specific probiotic properties; novel pharmaceutical compositions and food additives comprising such microorganisms and adherence factors |
| 04/24/1997 | WO1997014801A1 Novel cell surface protein compounds |
| 04/24/1997 | WO1997014800A1 Novel saliva binding protein |
| 04/24/1997 | WO1997014797A2 Cystatin m, a novel cysteine proteinase inhibitor |
| 04/24/1997 | WO1997014714A1 The aiolos gene |
| 04/24/1997 | WO1997014442A1 Hormone immunomodulated induction of mucosal immune responses |
| 04/24/1997 | WO1997014441A1 Method for restoring glucose responsiveness to insulin secretion |
| 04/24/1997 | WO1997014425A1 Two novel genes from psoriatic epidermis: psoriastatin type i and psoriastatin type ii |
| 04/24/1997 | WO1997014307A1 Method for treating ischemic tissue |
| 04/24/1997 | WO1997011968A3 A gene associated with liver neoplastic disease |
| 04/24/1997 | WO1997007784A3 LIPOSOMAL PHOSPHODIESTER, PHOSPHOROTHIOATE, AND p-ETHOXY OLIGONUCLEOTIDES |
| 04/24/1997 | WO1997006258A3 CDNA sequence, amino-acid sequence, derived from the CDNA sequence, of the precursor protein of human GCAP-II/uroguanyline, and amino-acid sequence of the fragment circulating in human blood |
| 04/24/1997 | WO1997005267A3 Mucosal delivery of polynucleotides |
| 04/24/1997 | WO1996040964A3 Lipid-nucleic acid particles prepared via a hydrophobic lipid-nucleic acid complex intermediate and use for gene transfer |
| 04/24/1997 | WO1996034107A3 Antiviral proteins, dna coding sequences therefor, and uses thereof |
| 04/24/1997 | CA2234877A1 Herpesvirus vectors and their uses |
| 04/24/1997 | CA2233549A1 Method for restoring glucose responsiveness to insulin secretion |
| 04/23/1997 | EP0769063A1 Targeted gene delivery system |
| 04/23/1997 | EP0769062A2 Novel internal ribosome entry site, vector containing same and therapeutical use thereof |
| 04/23/1997 | EP0769060A1 Fas associated proteins |
| 04/23/1997 | EP0769059A1 Manipulation of protoporphyrinogen oxidase enzyme activity in eukaryotic organisms |
| 04/23/1997 | EP0769023A1 Retinoic acid receptor epsilon |
| 04/23/1997 | EP0769021A2 Transgenic fish in the treatment of diabetes |
| 04/23/1997 | EP0768894A1 Multi-stage cascade boosting vaccine |
| 04/23/1997 | EP0768893A1 Polynucleotide vaccine for papillomavirus |
| 04/23/1997 | EP0768869A1 Factor to grow tissue ex vivo |
| 04/23/1997 | EP0749472A4 Extracorporeal cell culture and transplantation kits |
| 04/23/1997 | EP0400047B1 Modified hepatocytes and uses therefor |
| 04/22/1997 | US5623065 Gapped 2' modified oligonucleotides |
| 04/22/1997 | US5622853 Specific antigens |
| 04/22/1997 | US5622829 Genetic engineering |
| 04/17/1997 | WO1997014038A1 Methods to identify modulators of cell signaling |
| 04/17/1997 | WO1997013866A2 Recombinant herpes virus vectors for expression in neuronal cells |
| 04/17/1997 | WO1997013861A1 Composition and method of imparting resistivity to hiv superinfection to cells |
| 04/17/1997 | WO1997013857A1 Combination pdgf, kgf, igf and igfbp for wound healing |
| 04/17/1997 | WO1997013856A1 Improvements in or relating to protection against intracellular infection |
| 04/17/1997 | WO1997013778A1 A metastasis suppressor gene |
| 04/17/1997 | WO1997013530A1 USE OF A VECTOR CAUSING Bcl-2 EXPRESSION OR A TEMPORARY INCREASE IN Bcl-2 ACTIVITY |
| 04/17/1997 | WO1997013501A1 Liposomal compositions and methods of using them |